Linked Life Data

20144689

Source:http://linkedlifedata.com/resource/pubmed/id/20144689

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-3-15
pubmed:abstractText
Pioglitazone is an FDA-approved peroxisome proliferator activated receptor gamma (PPARgamma) agonist. We tested the hypothesis that treatment with pioglitazone reduces new lesion development in patients with RRMS. Twenty-two patients were treated with pioglitazone or placebo and monitored by diffusion tensor imaging (DTI) at baseline and after 12 months. A negative correlation was found between the 1-year change in relative anisotropy (RA) and fluid attenuated inversion recovery (FLAIR) lesion burden in the pioglitazone group. Regions of interest (ROIs) having high ADC and low RA values at baseline had a significantly higher chance to develop into lesions in the placebo group than similar ROIs in the pioglitazone group. These findings suggest that baseline DTI parameters can provide a prognostic surrogate marker for lesions, and that pioglitazone can reduce conversion of normal appearing white matter to lesions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1872-7972
pubmed:author
pubmed:copyrightInfo
2010 Elsevier Ireland Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
26
pubmed:volume
472
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
153-6
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients.
pubmed:affiliation
Department of Anesthesiology, University of Illinois, Chicago, IL 60612, USA.
pubmed:publicationType
Journal Article, Clinical Trial